A Texas organization has doled out millions to Houston cancer-fighting professionals

granted

Texas doctors and researchers received millions for their transformational work in cancer prevention and treatment. Getty Images

Researchers at medical institutions across the state have something to celebrate. The Cancer Prevention and Research Institute of Texas has made 71 grants this week to cancer-fighting organizations that total a near $136 million.

"CPRIT's priorities of pediatric cancer research and cancers of significance to Texans highlight this large slate of awards," says Wayne Roberts, CPRIT CEO, in a release. "Investments are made across the cancer research and prevention continuum in Texas unlike any other state in the country."

New to the awards this time around is the Collaborative Action Program for Liver Cancer, which has been claimed by Baylor College of Medicine's Hashem B. El-Serag.

"Texas has the highest incidence rates of hepatocellular cancer in the nation," El-Serag says in a release from BCM. "Our CPRIT funded Center will house infrastructure to support and enhance research collaborations among liver cancer researchers; to educate providers, researchers and the general public on best practices and opportunities to reduce the burden of liver cancer; and to engage private and public entities in policy initiatives."

Houston organizations also received recruitment awards, which reward Texas organizations for bringing in great minds from across the world. According to the release, CPRIT has brought in a total of 181 scholars and 13 companies to the Lone Star State.

Of the 71 grants, 58 represent academic research, 10 prevention, and three product development research. Here are the ones awarded to Houston organizations.

The University of Texas MD Anderson Cancer Center

  • $900,000 granted for Shao-Cung Sun's research in regulation of CD8 T cell responses in antitumor immunity (Individual Investigator Research Award)
  • $897,483 granted for Alemayehu A. Gorfe's research in characterization and optimization of novel allosteric KRAS inhibitors (Individual Investigator Research Award)
  • $3 million granted for Hashem B. El-Serag's research at The Texas Collaborative Center for Hepatocellular Cancer (Collaborative Action Program to Reduce Liver Cancer Mortality in Texas: Collaborative Action Center Award)
  • $2.46 million to Jessica Hwang for patient-centered liver cancer prevention in the Houston community (Collaborative Action Program to Reduce Liver Cancer Mortality in Texas: Investigator-Initiated Research Awards)
  • $3.51 million for Kevin McBride's Recombinant Antibody Production Core at Science Park
  • $199,804 granted for Andrea Viale's epithelial memory of resolved inflammation as a driver of pancreatic cancer progression (High Impact High Risk Award)
  • $6 million for the recruitment of Christopher Flowers, M.D. (Recruitment of Established Investigator Awards)
  • $2 million for the recruitment of Kevin Nead, MD, MPhil (Recruitment of First-Time, Tenure-Track Faculty Members Awards)
  • $2 million for the recruitment of Alison Taylor, PhD (Recruitment of First-Time, Tenure-Track Faculty Members Awards)
  • $2 million for the recruitment of Mackenzie Wehner, MD, MPhil (Recruitment of First-Time, Tenure-Track Faculty Members Awards)

Baylor College of Medicine

  • $5.38 million granted for Steven J. Ludtke's new capabilities for cancer research in the TMC CryoEM Cores (Core Facility Support Awards)
  • $1.35 million granted for Bryan M. Burt's novel endoscope-cleaning port for minimally invasive cancer surgery (Early Translational Research Awards)
  • $199,500 granted for Yohannes T. Ghebre's Topical Esomeprazole for Radiation-induced Dermatitis (High Impact High Risk Award)
  • $199,920 granted for Robin Parihar's targeting of cancer associated fibroblasts with anti-IL-11-secreting CAR T cells (High Impact High Risk Award)
  • $2 million for the recruitment of Umesh Jadhav, PhD (Recruitment of First-Time, Tenure-Track Faculty Members Awards)
  • $2 million for the recruitment of Stanley Lee, PhD (Recruitment of First-Time, Tenure-Track Faculty Members Awards)
  • $2 million for the recruitment of Ang Li, MD (Recruitment of First-Time, Tenure-Track Faculty Members Awards)
  • $1.29 million for Jane R. Montealegre's expansion of "a Community Network for Cancer Prevention to Increase HPV Vaccine Uptake and Tobacco Prevention in a Medically Underserved Pediatric Population"

Texas Medical Center

  • $5.44 million granted for William McKeon's Business-Driven Accelerator for Cancer Therapeutics (Core Facility Support Awards)

The University of Texas Health Science Center at Houston

  • $5.95 million granted for Zhiqiang An's Advanced Cancer Antibody Drug Modalities Core Facility (Core Facility Support Awards)
  • $2 million granted for Qingyun Liu's discovery and development of novel peptibody-drug conjugate for treating cancers of the digestive system (Early Translational Research Awards)
  • $199,998 granted for Leng Han's expression landscape and biomedical significance of transfer RNAs in cancer (High Impact High Risk Award)
  • $2 million for Lara S. Savas' Salud en Mis Manos that delivers "Evidence-Based Breast & Cervical Cancer Prevention Services to Latinas in Underserved Texas South and Gulf Coast Communities"

The University of Texas Medical Branch at Galveston

  • $3.55 million granted for William K. Russell's A Targeted Proteomics and Metabolomics Mass Spectrometry Core Facility at the University of Texas Medical Branch at Galveston (Core Facility Support Awards)
  • $199,996 granted for Brendan Prideaux's novel cellular-level imaging approach to assess payload drug distribution in tumors following administration of targeted drug delivery systems (High Impact High Risk Award)
  • $200,000 granted for Casey W. Wright's targeting ARNT and RBFOX2 alternative splicing as a novel treatment modality in lymphoid malignancies (High Impact High Risk Award)

The Methodist Hospital Research Institute

  • $200,000 granted for Robert Rostomily's development of a mini-pig glioma model and validation of human clinical relevance (High Impact High Risk Award)

Texas Southern University

  • $200,000 for Song Gao's alleviating SN-38-induced late-onset diarrhea by preserving local UGTs in the colon (High Impact High Risk Award)

University of Houston

  • $200,000 granted for Sergey S. Shevkoplyas' Novel High-Throughput Microfluidic Device for Isolating T-cells Directly from Whole Blood to Simplify Manufacturing of Cellular Therapies (High Impact High Risk Award)

Rice University

  • $2 million for the recruitment of Jiaozhi (George) Lu, PhD (Recruitment of First-Time, Tenure-Track Faculty Members Awards)
  • $1.67 million for the recruitment of Vicky Yao, PhD (Recruitment of First-Time, Tenure-Track Faculty Members Awards)

The Rose

  • $2 million for Bernice Joseph's Empower Her To Care Expansion

Legacy Community Health Services

  • $999,276 for Charlene Flash's "Increasing Breast and Colorectal Cancer Screening Rates for the Medically Underserved using Population Health Strategies at a Multi-County FQHC"
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston startup secures $22.5M to innovate cell therapy to fight cancer

fresh funding

A promising cell therapy company has raised its latest funding round — to the tune of $22.5 million.

Indapta Therapeutics, which has a dual headquarters in Houston and Seattle, is a clinical stage biotechnology and next-generation cell therapy company focused on the treatment of cancer and autoimmune diseases. The company announced it has closed a $22.5 million round of new financing to accelerate the clinical development of its differentiated allogeneic Natural Killer cell therapy.

"This funding will enable us to generate significant additional data in our ongoing trial of IDP-023 in cancer as well as initial data from our first trial in autoimmune disease," Mark Frohlich, Indapta’s CEO, says in a news release.

Indapta has completed enrollment in the safety run-in portion of the Phase 1 clinical trial of IDP-023 in Non-Hodgkin’s Lymphoma and Multiple Myeloma, according to the company. The patients received up to three doses of IDP-023 without and with interleukin (IL)-2.

Completing the round were current investors RA Capital Management, Bayer's impact investment arm Leaps, Vertex Ventures HC, Pontifax, and the Myeloma Investment Fund, the venture philanthropy subsidiary of the Multiple Myeloma Research Foundation. Earlier in December, Indapta announced a collaboration with Sanofi to explore the combination of its allogeneic g-NK cell therapy IDP-023 with Sanofi’s CD38 that targets the monoclonal antibody, Sarclisa (isatuximab).

"Preliminary results of IDP-023 in cancer are encouraging and we look forward to initiating our Phase 1 trial for multiple sclerosis in Q1 2025,” Frohlich continues. “This financing, together with our recently announced collaboration with Sanofi, highlights the promise of our differentiated platform.”

Also in August, Indapta announced a FDA clearance of its IND of IDP-023 in combination with ocrelizumab in progressive MS.


Mark Frohlich is the CEO of the Houston- and Seattle-based company. Photo courtesy of Indapta Therapeutics

Houston startup's revolutionary automotive recycling tech to begin commercial operations

houston innovators podcast episode 267

Vibhu Sharma observed a huge sustainability problem within the automotive industry, and he was tired of no one doing anything about it.

"Globally, humans dispose 1 billion tires every year," Sharma says on the Houston Innovators Podcast. "It's a massive environmental and public health problem because these tires can take hundreds of years to break down, and what they start doing is leaking chemicals into the soil."

Today, 98 percent of all tires end up in landfills, Sharma says, and this waste contributes to a multitude of problems — from mosquito and pest infestation to chemical leaks and fire hazards. That's why he founded InnoVent Renewables, a Houston-based company that uses its proprietary continuous pyrolysis technology to convert waste tires into valuable fuels, steel, and chemicals.

While the process of pyrolysis — decomposing materials using high heat — isn't new, InnoVent's process has a potential to be uniquely impactful. As Sharma explains on the show, he's targeting areas with an existing supply of waste tires. The company's first plant — located in Monterrey, Mexico — is expected to go online early in the new year, an impressive accomplishment considering Sharma started his company just over a year ago and bootstrapped the business with only a friends and family round of funding.

"It's about 16 months or so from start to commercial operations, which is phenomenal when you consider what it takes to build and operate a chemical or petrochemical facility," Sharma says.

Currently, with the facility close to operations, Sharma is looking to secure customers for the plant's products — which includes diesel, steel, and carbon black — and he doesn't have to look too far out of the automotive industry for his potential customer base. Additionally, the plant should be net zero by day one, since Sharma says he will be using the output to fuel operations.

While the first facility is in Mexico, Sharma says they are already looking at potential secondary locations with Texas at the top of his list. Houston, where Sharma has worked for 26 years, has been a strategic headquarters for InnoVent.

"When it came to doing the research and development, we were able to work with experts in the Houston and Texas areas to test out our idea and validate it," Sharma says. "One thing that gets under appreciated about Houston is how well it's connected to the rest of the world. There are so many direct connections between Houston and Latin America, as well as Europe, Middle East, and Asia."

"I also find that the Houston ecosystem is very supportive of new companies and helping them grow," he adds.

Houston expert on what AI is changing in the workplace — and why employers need to recognize the 'human edge'

guest column

When OpenAI's GPT-4 made headlines by passing the bar exam and scoring in the top 10 percent on medical licensing tests, I noticed something fascinating: everyone focused on AI replacing professionals, but they missed the deeper story. AI isn't just disrupting work – it's exposing fundamental flaws in how we've built our entire workplace ecosystem. It's holding up a mirror to our organizations, revealing just how far we've strayed from what makes us uniquely human.

The World Economic Forum tells us 44 percent of workers' skills will need updating by 2027, but that statistic only scratches the surface. In my conversations with business leaders, I'm watching a transformation unfold in real-time. Take the accounting industry, where I've observed forward-thinking firms like Deloitte and PwC turning their accountants into strategic business advisors while other firms continue training junior staff for tasks that AI will soon handle. This isn't just a skills mismatch – it's a fundamental misunderstanding of human potential.

The challenge runs deeper than individual industries. McKinsey predicts 30 percent of hours worked globally could be automated by 2030, but I believe they're missing a crucial point. We've spent decades designing jobs around industrial-era ideals of efficiency and standardization – the very qualities that make them perfect targets for AI automation. In our obsession with measuring, standardizing, and streamlining everything, we've created workplaces that treat humans like machines rather than the complex, creative beings we are.

What's emerging is a striking paradox: as work becomes more automated, our workplace cultures are growing more disconnected. Microsoft researchers identified a "collaboration deficit" in remote work environments, with 56 percent of employees reporting a decline in workplace friendships. This cultural shift is occurring precisely when we need human connection most. During the Great Resignation of 2021, 47 million Americans quit their jobs, they weren't leaving because of salary considerations or technological inadequacies. The most common reasons cited were lack of human connection, purpose, and authentic leadership.

Yet instead of heeding this wake-up call, the rise of AI is pushing us further apart. A decade ago, the concept of "workplace family" was commonplace – now it's often dismissed as manipulative corporate rhetoric. This shift reveals a troubling blindspot in our thinking about work. Consider this: we spend more than 90,000 hours at work over our lifetime – more time than we spend with our own families – yet we're increasingly treating these relationships as purely transactional. In our rush to establish boundaries and protect ourselves from corporate exploitation, we've overcorrected, creating sterile workplaces stripped of human connection.

This timing couldn't be worse. As someone who studies the intersection of technology and workplace culture, I've observed a clear pattern: the more we automate routine tasks, the more our success depends on distinctly human qualities like trust, emotional sensitivity, and the ability to navigate complex interpersonal dynamics. Yet we're systematically dismantling the very cultural foundations that enable these qualities to flourish. It's as if we're entering a boxing match by tying one hand behind our back – at precisely the moment we need every advantage we can get.

The real crisis isn't that AI might replace jobs – it's that we're creating workplace environments that suppress the very qualities that make us irreplaceable. When we treat our colleagues as mere interfaces rather than complex human beings, we don't just damage relationships – we damage our capacity for innovation, creativity, and the kind of deep collaboration that complex problem-solving requires.

Some companies are starting to get it right. When I look at examples like IKEA, who chose to retrain their call center workers as interior design advisors rather than simply replacing them with chatbots, I see a glimpse of what's possible. They recognized something profound: you can't automate the human ability to understand what a frustrated customer really needs, or the intuition to read between the lines of what they're saying.

This is what I call the "human edge" – and it's far more nuanced than most leadership teams realize. It's the marketing manager who can sense team tension during a video call and address it before it derails a project. It's the sales representative who builds such strong relationships that clients stay loyal through market upheavals. It's the team leader who knows exactly when to push for more and when to show compassion. These aren't just nice-to-have soft skills – they're becoming our most valuable business assets.

But here's the challenge: we're still trying to measure workplace success like it's 1990. We track productivity metrics, sales numbers, and project timelines, but how do we quantify someone's ability to defuse a tense client situation? How do we measure the value of a team leader who creates an environment where people feel safe to innovate? These human capabilities – empathy, emotional intelligence, relationship building, creative problem-solving – are increasingly what separate successful companies from failing ones, yet they're nearly impossible to capture in a performance review.

When I talk to business leaders, I tell them bluntly: if a job can be reduced to a process, AI will eventually do it better. Our value lies in all the messy, human things that happen between the bullet points of a job description. Instead of asking "How many tasks did you complete?" we should be asking "How did you help your team navigate that difficult change?" Instead of training people to follow processes, we should be developing their ability to build relationships and navigate complexity.

It's time we started treating these human capabilities not as soft skills, but as core business competencies. The question isn't whether AI will change work – it's whether we'll use this moment to finally build workplaces that enhance rather than diminish our humanity.

———

Nada Ahmed is the founding partner at Houston-based Energy Tech Nexus and author of Amazon Bestseller “Determined to Lead- The Disruptive Woman's Guide to Stop Playing Small and Transform your Career through Agile Leadership.”

View All Listings